期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

对氧磷酯酶与缺血性血管疾病 被引量：1

Paraoxonase and ischemic vascular disorders
下载PDF
导出
作者 周玉颖
机构地区 天津市环湖医院神经内科
出处 《中国现代神经疾病杂志》 CAS 2004年第6期382-384,共3页 Chinese Journal of Contemporary Neurology and Neurosurgery
基金 天津市卫生局科技基金资助项目(03CJ07)
关键词 对氧磷酯酶1 缺血性 血管疾病 高密度脂蛋白 初发 动脉粥样硬化性疾病 免疫炎症反应 脂质过氧化物 分子机制 血清
分类号 R543 [医药卫生—心血管疾病]
  • 相关文献

参考文献23

  • 1[1]Mackness MI, Mackness B, Durington PN, et al. Paraoxonase and coronary heart disease.Curr Opin Lipidol, 1998, 9:319-324.
  • 2[2]Rosenblat M, Hayek T, Hussein K, et al.Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler Thromb Vasc Biol, 2004, 24:175-180.
  • 3[3]Reddy ST, Wadleigh DJ, Grijalva V, et al.Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol, 2001, 21:542-547.
  • 4[4]Deakin S, Leviev T, Guernier S, et al. Simvastatin modulates expression of the PON1gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol,2003, 23:2083-2089.
  • 5骆杨平.屏氧酶-1与动脉粥样硬化[J].心脑血管病防治,2002,2(2):40-42. 被引量：1
  • 6[7]Boemi M, Sirolla C, Testa R, et al. Smoking is associated with reduced serum levels of the antioxidant enzyme, paraoxonase, in Type 2 diabetic patients. Diabet Med, 2004,21:423-427.
  • 7[8]Kopprasch S, Pietzsch J, Kuhlisch E, et al.Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. Clin Endocrinol Metab, 2003,88:1711-1716.
  • 8[9]Rozenberg O, Shih DM, Aviram M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol, 2003, 23:461-467.
  • 9[10]Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid ayherosclerotic lesions:PON1 esterase and peroxidase-like activities. Circulation, 2000, 101:2510-2517.
  • 10[11]Jakubowski H, Ambrosius WT, Pratt H. Genetic determinants of homocysteine thiolactonase activity in humans:implications for atherosclerosis. FEBS Lett, 2001, 491:35-39.

二级参考文献41

  • 1[1]Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase like activities. Circulation, 2000, 30:2510
  • 2[2]McElveen J, Mackness MI, Colley CM, et al. Distribution of paraoxon hydrolitic activity in the serum of patients after myocardial infarction, Clin Chem, 1986, 32:671
  • 3[3]Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis, 1991, 86:193
  • 4[4]Furlong CE, Richter RJ, Seidel SL, et al. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolisis of the insecticide metabolites chlorpyifos oxon and paraoxon. Am J Hum Genet, 1988, 43:230
  • 5[5]Steinberg D. Lipoproteins and atherosclerosis:a look back and a look ahead. Arteriosclerosis, 1983, 3:283
  • 6[6]Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol:Modification of low-density lipoprotein that increase its atherogenicity. New England J Medicine, 1989, 320(14):915
  • 7[7]Gordon D. In:Durrington PN(ed). HDL:Where should the clinician stand? London:Mark Allen Publishing, 1992,17
  • 8[8]Klimov AN, Kozhemyakin LA, Pleskov VM, et al. Antioxidative effect of high density lipoprotein in the oxidation of low density lipoprotein. Bull Exp Biol Med, 1987, 103:550
  • 9[9]Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein (HDL) oxidation and preserves its functions. J Clin Invest, 1998, 101:1581
  • 10[10]Mackness B, Mackness MI, Arol S, et al. Effect of human serum paraoxonase 55 and 192 genetic polymorphism on the protection by high density lipoprotein oxidative modification. FEBS Lett, 1998, 423(1):57

共引文献5

同被引文献11

  • 1Durrington PN,Mackness B,Mackness MI.Paraoxonase and atherosclerosis[J].Arterioscler Thromb Vasc Biol,2001,21:473-480.
  • 2Voetsch B,Benke KS,Damasceno BP,et al.Paraoxonase 192 Gln/ Arg polymorphism:an independent risk factor for nonfatal arterial ischemic stroke among young adults[J].Stroke,2002,33:1459-1464.
  • 3The International HapMap Consortium.The International HapMap Project[J].Nature,2003,426:789-796.
  • 4No authors listed.Stroke--1989.Recommendations on stroke prevention,diagnosis,and therapy.Report of the WHO Force on Stroke and other Cerebrovascular Disorders[J].Stroke,1989,20:1407-1431.
  • 5Adams HP Jr,Bendixen BH,Kapplle LJ,et al.Classification of subtype of acute ischemic stroke.Definitions for use in a multicenter clinical trial.Trial of Org 10172 in Acute Stroke Treatment[J].Stroke,1993,24:35-41.
  • 6Adikins S,Gan KN,Mody M,et al.Molecular basis for polymorphic forms of human serum paraoxonase/ arylesterase:glutamine or arginine at position 191,for the respective A or B allozymes.[J].Am J Hum Genet,1993,52:598-608.
  • 7The International HapMap Consortium.A haplotype map of the human genome[J].Nature,2005,437:1299-1320.
  • 8Aviram M,Rosenblat M.Paraoxonases and cardiovascular diseases:pharmacological and nutritional influences[J].Curr Opin Lipidol,2005,16:393-399.
  • 9Baum L,Ng HK,Woo KS,et al.Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk[J].Clin Biochem,2006,39:191-195.
  • 10Schmidt R,Schmidt H,Fazekas F,et al.MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms:three-year follow-up of the austrian stroke prevention study[J].Arterioscler Thromb Vasc Bio,1 2000,20:1811-1186.

引证文献1

中国现代神经疾病杂志
2004年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部